Safety and Pharmacokinetic Study of Intranasal 2-DG in Healthy Volunteers

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2022
2-DG-01 is a randomized, double-blind, placebo-controlled, single and multiple ascending dose phase 1 study assessing safety, tolerability and pharmacokinetics of 2-DG in normal healthy volunteers (NHV). The safety and pharmacokinetics of 2-DG are assessed after single or multiple intranasal administrations.
Epistemonikos ID: c77b95f42383b32e891eaf2e3c5f0d9eb48a1e8a
First added on: May 13, 2024